Experimental combo targets tough blood cancers
NCT ID NCT03326310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of two drugs, selumetinib and azacitidine, in adults with higher-risk blood cancers like MDS and myelofibrosis. The main goal is to find the safest dose of selumetinib when given with standard azacitidine and to monitor side effects. Participants will continue treatment as long as it helps, and the study will follow them for about 24 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can donor immune cells tame stem cell transplant risks?